Annovis Bio secures buntanetap patent

Annovis Bio, a Phase 3 clinical-stage biotechnology company, announced the issuance of U.S. Patent No. 12,582,632 B2. This patent covers the prevention and treatment of neurological injuries stemming from brain infections through the administration of buntanetap, its investigational oral therapy. The patent's significance lies in its potential to address Alzheimer s disease pathology linked to infectious agents, such as viruses and bacteria, which are hypothesized to trigger the overproduction of neurotoxic proteins. Buntanetap's mechanism of action, which reduces the overproduction of these proteins, positions it as a relevant candidate for this application. The patent protection extends through 2044 and includes claims for both preventive use and reversal of neurological damage. Maria Maccecchini, President and CEO of Annovis Bio, emphasized the patent's importance in expanding the company's intellectual property and addressing complex neurodegenerative diseases.